Is azo (phenazopyridine) safe to use for symptomatic relief of a urinary tract infection (UTI) in a pregnant patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Phenazopyridine (Azo) Safety in Pregnancy for UTI Symptom Relief

Phenazopyridine is classified as FDA Pregnancy Category B and can be used during pregnancy for symptomatic relief of UTI-related dysuria, but it should only be used as a short-term adjunct (maximum 2 days) alongside appropriate antibiotic therapy, not as standalone treatment. 1

FDA Safety Classification

  • The FDA drug label indicates that reproduction studies in rats at doses up to 50 mg/kg/day revealed no evidence of impaired fertility or harm to the fetus due to phenazopyridine. 1
  • However, there are no adequate and well-controlled studies in pregnant women, so the drug should be used during pregnancy only if clearly needed. 1
  • No information is available on the appearance of phenazopyridine or its metabolites in human milk, which is an important consideration for breastfeeding. 1

Critical Clinical Context: UTIs in Pregnancy Require Antibiotic Treatment

All bacteriuria in pregnancy—whether symptomatic or asymptomatic—must be treated with antibiotics, not just symptomatic relief agents. 2, 3

  • Pregnant women with untreated asymptomatic bacteriuria have a 20-30-fold increased risk of developing pyelonephritis compared to women without bacteriuria. 2, 4
  • Without antibiotic treatment, pyelonephritis develops in 20-35% of pregnant women with bacteriuria, compared to only 1-4% when treated. 2, 4
  • Untreated UTIs are associated with premature delivery, low birth weight infants, and other adverse maternal and fetal outcomes. 2, 4, 5

Appropriate Use of Phenazopyridine in Pregnancy

If phenazopyridine is used, it should only serve as a bridge for symptomatic relief during the first 24-48 hours while waiting for antibiotics to take effect:

  • The primary treatment must be appropriate antibiotics such as nitrofurantoin, fosfomycin trometamol, amoxicillin, or third-generation cephalosporins (cefixime). 2, 6, 7
  • Phenazopyridine only provides symptomatic relief of dysuria, urgency, and frequency—it does not treat the underlying infection. 1
  • Duration should be limited to 2 days maximum, as prolonged use increases risk of accumulation, especially given the physiological changes in renal function during pregnancy. 1

Important Safety Precautions

  • Monitor for yellowish discoloration of skin or sclera, which may indicate accumulation due to impaired renal excretion and necessitates discontinuation. 1
  • Warn patients that phenazopyridine produces reddish-orange discoloration of urine and may stain fabric and contact lenses. 1
  • The drug may interfere with urinalysis based on spectrometry or color reactions, which could complicate follow-up testing. 1

Common Pitfall to Avoid

Never use phenazopyridine as monotherapy or allow it to delay appropriate antibiotic treatment. The physiological changes of pregnancy (ureteral compression by the enlarging uterus after 20 weeks, urinary stasis, physiological hydronephrosis) create an environment that promotes ascending infections. 4 Any delay in antibiotic therapy significantly increases the risk of progression to pyelonephritis with its associated maternal and fetal complications. 2, 4

Recommended Antibiotic Options for UTI in Pregnancy

  • First-line oral options: Nitrofurantoin, fosfomycin trometamol (single dose), or amoxicillin for 4-7 days. 2, 8, 6, 7
  • Alternative oral options: Third-generation cephalosporins such as cefixime. 6, 7
  • For pyelonephritis: Amoxicillin combined with an aminoglycoside, third-generation cephalosporins, or carbapenems (parenteral). 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Indications for Treating Asymptomatic UTI

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

UTI Risk Factors During Pregnancy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Urinary tract infections in pregnancy.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2023

Research

Vigilance on use of drugs, herbal products, and food supplements during pregnancy: focus on fosfomycin.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.